高密度乳房組織を有する患者のスクリーニングにおける分子乳房イメージングおよびデジタル乳房トモシンセシス
Density Matters [ReServoir を排除するための分子乳房イメージング (MBI) とトモシンセシス]
This study compares molecular breast imaging (MBI) and digital breast tomosynthesis (DBT) in screening patients with dense breast tissue. Breast imaging may help doctors find breast cancer sooner, when it may be easier to treat. Molecular breast imaging (MBI) uses an injection of a small amount of radioactive material that is taken up in tissues of the body that are actively changing, such as breast cancer. A specialized camera, called a gamma camera, takes pictures of the gamma rays emitted by this material. MBI may detect cancers that are not visible on mammograms. This study may help researchers determine how MBI testing compares to DBT screening.
調査の概要
詳細な説明
This study includes women age 40-75 who are presenting for breast cancer screening and had mammographically dense breasts on their last mammogram. Participants undergo annual DBT and MBI screening for two years. The primary aim for this study is to compare the rate of detection of invasive cancers between DBT alone vs. the combination of DBT with supplemental MBI at the first year of screening.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Michigan
-
Detroit、Michigan、アメリカ、48202
- Henry Ford Hospital
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic in Rochester
-
-
Ohio
-
Toledo、Ohio、アメリカ、43623
- Toledo Clinic Cancer Centers-Toledo
-
-
Texas
-
Houston、Texas、アメリカ、77030
- M D Anderson Cancer Center
-
-
Wisconsin
-
La Crosse、Wisconsin、アメリカ、54601
- Mayo Clinic Health System-Franciscan Healthcare
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patient is a consenting female age 40-75 years
- Patient is scheduled for routine screening DBT
- Patient is asymptomatic for breast disease
- Patient had heterogeneously dense or extremely dense breasts on most recent prior mammography examination (Breast Imaging Reporting and Data System [BI-RADS] c or d) within 24 months of enrollment
- Patient is able to participate fully in all aspects of the study (completing study visits and study data collection)
- Patient understands and signs the study informed consent
- Patient anticipates being able to return one year after study enrollment to complete the second round of screening
Exclusion Criteria:
- Patient is currently pregnant or plans to become pregnant during the course of the study
- Patient is currently lactating
- Patient has had a prior MBI
- Patient has had a prior whole breast ultrasound (WBUS) for screening, with either a hand-held ultrasound probe or automated system, within 12 months prior to study enrollment
- Patient has had a prior breast MRI
- Patient has had a prior contrast-enhanced mammogram (contrast enhanced spectral mammography [CESM] or contrast-enhanced digital mammography [CEDM])
- Patient is concurrently participating in any other breast imaging research studies that involve undergoing additional breast imaging tests beyond routine screening with mammography, including but not limited to contrast-enhanced mammography, WBUS, MBI, or contrast-enhanced breast MRI
- Patient has had a breast biopsy within 3 months prior to study enrollment
- Patient has had breast surgery within 12 months prior to study enrollment
- Patient is currently undergoing treatment for breast cancer or planning surgery for a high-risk breast lesion (atypical ductal hyperplasia [ADH], atypical lobular hyperplasia [ALH], lobular carcinoma in situ [LCIS], papilloma, radial scar)
- Patient is currently taking a chemoprevention agent for breast cancer risk reduction or osteoporosis prevention (tamoxifen, raloxifene, anastrazole, letrozole, exemestane)
- Patient has a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder study adherence
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：診断
- 割り当て：非ランダム化
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：DBT alone
All participants undergo DBT screening |
DBT is standard of care breast screening
他の名前：
|
|
実験的：DBT + MBI
All participants undergo DBT screening + supplemental MBI |
DBT is standard of care breast screening
他の名前：
Undergo MBI
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rate of Detection of Invasive Cancers
時間枠：At year 1 screening
|
Compare the rate of detection of invasive cancers between DBT alone versus (vs.) the combination of digital breast tomosynthesis (DBT) with supplemental molecular breast imaging (MBI) at initial (year 1) screening. For each modality, the detection rate of invasive cancers will be estimated as the proportion of participants in the analysis set who had an invasive cancer detected by the modality and verified by pathology. |
At year 1 screening
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Carrie B. Hruska, M.D.、Mayo Clinic in Rochester
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。